The evaluation of potency plays a key role in defining the quality of cellular therapy products (CTPs). Potency can be defined as a quantitative measure of relevant biologic function based on the attributes that are linked to relevant biologic properties. To achieve an adequate assessment of CTP potency, appropriate in vitro or in vivo laboratory assays and properly controlled clinical data need to be created. The primary objective of a potency assay is to provide a mechanism by which the manufacturing process and the final product for batch release are scrutinized for quality, consistency and stability. A potency assay also provides the basis for comparability assessment after process changes, such as scale-up, site transfer and new starting materials (e.g., a new donor). Potency assays should be in place for early clinical development, and validated assays are required for pivotal clinical trials. Potency is based on the individual characteristics of each individual CTP, and the adequacy of potency assays will be evaluated on a case-by-case basis by regulatory agencies. We provide an overview of the expectations and challenges in development of potency assays specific for CTPs; several real-life experiences from the cellular therapy industry are presented as illustrations. The key observation and message is that aggressive early investment in a solid potency evaluation strategy can greatly enhance eventual CTP deployment because it can mitigate the risk of costly product failure in late-stage development.
Scope
In recent years, several cellular therapy products (CTPs) for regenerative or immune therapy applications have advanced to pivotal clinical evaluation and market authorization (1) . The successful deployment of CTPs is hindered to a great extent by their complexity, which makes identification of relevant biologic activities-and thus definition of consistent CTP quality-difficult. Although the regulatory requirement for potency assays is well understood by CTP developers, existing guidelines and articles generally either discuss their development in isolation or mention them briefly in the context of characterization. Feedback from International Society for Cell Therapy (ISCT) members suggested the need to explain the available regulatory guidance and provide examples of how others in the field have tackled the problem. To this end, the ISCT Process and Product Development Subcommittee formed a potency working group at the 17th annual ISCT meeting in Rotterdam, the Netherlands, in 2011 to address this commercial need. A resulting objective of this review is to provide a broader explanation of why potency assessment is such a critical part of characterization and the control of product quality and consistency not only during development but also over the entire product life cycle.
If the intended action of the product and its accompanying regulatory status are overlooked, existing guidance and literature regarding potency assays might be subject to certain misconceptions. For the purpose of this review, CTPs are autologous, allogeneic or xenogeneic cells for therapeutic, diagnostic or preventive purposes in humans. For reasons of brevity, this review excludes products consisting of cells combined with non-cellular components (e.g., scaffolds, devices) and genetically modified cell products, for which additional regulations and characterization needs exist. Cell transplantation (i.e., homologous use of minimally manipulated cells) and CTPs regulated primarily as devices are also deliberately excluded because their mechanism of action (MOA) is not intended to be primarily medicinal. In cases where the intended mechanism is primarily physical, determination of its quality is primarily through physical characteristics. For example, for the living cell-based combination product Apligraf (Organogenesis, Canton, MA, USA), which received pre-market approval from the U.S. Food and Drug Administration (FDA) in 1998 (2), potency is defined through physical characteristics evaluated by histologic techniques (3) . Likewise, the quality of a cell transplant can more plausibly be established by simple measurements such as viability because the cells are minimally manipulated.
Because published potency strategies are rare, the final objective of this review is to provide examples (see later case studies and Supplementary material) that have been developed for a range of patientspecific and off-the-shelf CTPs. Although these may not all prove successful in the long run, they emphasize the need for case-by-case development to deal with the differing issues and limitations.
Characterization
The first objective of CTP development should be to define the active substance and the critical quality attributes of the product so that these can be controlled. To meet this objective, it is necessary from the outset to characterize the product and its manufacturing process (including raw materials). Key terminology for cell characterization is provided in Table I . A more recent "publicly available specification" (4) provides further information on characterization of cells including description of potential methodologies and their strengths and limitations. Pritchett and Little (5) also recently reviewed potency requirements in the field.
The central principle in defining the quality of a CTP (as with all biologic products) is that although physicochemical parameters can identify the cellular active substance, including surface markers that are involved in function, they cannot confirm that the product will actually be biologically active and potent (i.e., elicit the desired effect). Consequently, physicochemical measurements are primarily used for identification and quantification of the active substance, intermediates, impurities and contaminants. It is important to acknowledge this limitation of physicochemical testing to understand why broad Table I . Definition of key terminology for cell product characterization.
Characterization parameter Definition
Physicochemical characterization
Refers to the use of methods that measure physical and chemical characteristics. Examples for CTP: Physical: size, morphology, light-scattering properties, tensile strength, cell number, confluence Chemical: identification of phenotypic markers and secreted substances, genotype, gene expression profile Biologic characterization
Refers to the use of methods that measure biologic function (i.e., how the physicochemical characteristics influence biologic systems). Examples for CTP: Biologic: in vitro or in vivo measurements of cytotoxicity, cell growth, de-differentiation, proliferation, migration, tissue remodeling Potency Comparability testing Exercise to evaluate the impact of changes to a manufacturing process on the validity of quality, non-clinical or clinical data relating to a CTP or its components Comparable c Conclusion that the product has highly similar quality attributes before and after manufacturing process changes and that no adverse impact on the safety or efficacy, including immunogenicity, of the product occurred Biocompatibility c Ability of a material to perform with an appropriate host response in a specific application Stability testing c Determination of the shelf life under storage and in use for the product and its intermediates Stability Duration over which the quality of the product is maintained within pre-defined parameters Release assay Validated test method with pre-defined acceptance criteria to which manufactured product needs to conform to be released for clinical use a Adapted from (6).
b
As a measure of relevant biologic function, potency should be based on biologic characterization. Where this is not feasible, a physicochemical measure may be used as a surrogate for potency at release or stability, as long as it can be correlated to a measure of relevant biologic function. c Adapted from (21) .
biologic characterization should be employed to investigate biologic function. In contrast, biologic characterization takes into account the effect of the product on biologic systems, either modeled in vitro or in vivo in animals and ultimately in the clinic. Although regulatory documentation divides quality from non-clinical and clinical evaluations, they are part of the same process and should not be considered in isolation. Where possible, biologic characterization should also aim to investigate the biologic activity of intermediates and impurities, and although such tests are not defined as potency assays, their purpose is broadly similar. In particular, these biologic assays are essential to confirm stability of intermediates such as cell banks as well as manufacturing hold steps and shipping. For impurities, biologic characterization normally focuses on in vivo toxicity testing, although it may also involve in vitro assays. Potency assays are tests that have been demonstrated, during development, to confirm that the relevant biologic functions of the CTP (ideally correlated to efficacy) are present.
Why is potency so important?
The ultimate aim of potency assessment is to identify the parameters that are critical to the efficacy of the product and to control them such that a product of consistent quality can be manufactured.
Without product consistency, it is unrealistic to expect consistent clinical effects.
The central role of potency in the various activities that are required to establish product quality is depicted in Figure 1 . Confirmation of biologic activity is needed to define the shelf life of the product (6) (viability may not be the most sensitive or relevant stability-indicating parameter) and to confirm compatibility of the product with other substances with which it comes in contact (e.g. delivery device, matrix material, primary container). More importantly, without measures of biologic activity (including potency), product comparability cannot be established after process changes without non-clinical or clinical testing (or both).
Development of CTPs is an expensive and timeconsuming endeavor. Funding is a precious commodity, and the needs and expectations of investors may frequently conflict with the CTP developers. Investors are not likely to view critical early development milestones such as the identification of a suitable potency assay as important as the regulatory approval of clinical trials or positive outcomes of the trials. From the investor perspective, this attitude makes sense; however, driving early clinical development at the expense of manufacturing and quality development brings significant risks. Identifying and developing potency assays yield critical tools that enable process changes in the future. Without these Figure 1 . Central role of potency assessment in the determination of CTP quality. Potency is central to biologic characterization, which, underwritten by the hypothesis for MOA together with a description of the physicochemical properties, provides the platform for product specification and analysis of product comparability, stability and compatibility. tools, even minor process changes could require clinical qualification, which would be costly and potentially commercially disastrous. Consequently, fast-to-phase III development programs that bypass detailed biologic characterization in the race to the clinic have a higher risk of failure or at best may be saddled with manufacturing limitations that compromise commercial success. Early and sustained investment in a bona fide potency program is essential for maximizing a product's commercial success.
Regulatory expectations for CTPs
The essential principle that active substances whose molecular structure cannot be fully defined require an evaluation of their potency before release onto the market is enshrined in the pharmaceutical legislation of both the United States (7) and European Union (8, 9) . It is a legal requirement to evaluate the potency of each batch of a licensed CTP. Although there are various references to the importance of potency assays throughout the International Conference on Harmonisation, European Medicines Agency (EMA) and FDA guidelines, to date only the FDA has compiled a comprehensive guidance document on potency testing for CTPs and gene therapy products (10) . The EMA, in contrast, has not yet written a general guideline for potency testing of CTPs, although the core multidisciplinary guideline (11) has a short section that also refers to a guideline on potency testing for immunotherapy products (12) .
The FDA and EMA recognize the challenges inherent in developing potency testing for CTPs and have adopted a flexible, although still rigorous, regulatory approach. Specifically, regulatory agencies acknowledge that potency evaluation is determined by the individual product characteristics and that the adequacy of potency assays consequently need to be evaluated on a case-by-case basis. All CTP developers have a responsibility to define and test the most suitable criteria and measures for potency assessment of their individual products; in certain cases, this may require establishing specific novel standards or procedures not yet covered by regulatory guidance. These existing guidelines are reviewed next with the key messages outlined. Core requirements for potency testing as defined by the FDA are presented in Table II .
Progressive implementation
CTP potency testing is expected to be developed over the course of pre-clinical and clinical development, becoming more sophisticated and defined with increasing understanding of the product and its functions. In the course of phase I and phase II trials, multiple characteristics and candidate assays should be evaluated, guided by proposed MOA and data from proof-of-concept studies. Early in clinical development, defined acceptance criteria, although desirable, are not required for potency testing. Both the FDA and the EMA expect potency testing with defined acceptance criteria to be in place before the start of pivotal clinical trials and potency testing validation to have been completed before submission of a market authorization.
This flexible regulatory approach to potency testing development must be matched by the CTP product developer. It may be necessary to adjust potency test methods and specifications in the course of clinical development to reflect manufacturing and clinical experience.
Regulatory core requirements
Although there is flexibility during development, the FDA specifies certain core requirements for CTP potency testing (Table II) . Potency testing must demonstrate the relevant biologic activity or activities of the product. It is not a requirement for potency testing to reflect all of the product's biologic functions, but it should indicate one or more relevant biologic functions. Testing all biologic functions of a product is rarely feasible, given the multimodal MOA of CTP. Testing a subset of the most relevant biologic function or functions is a practical, scientifically meaningful strategy that meets regulatory expectations.
Potency testing results are a required element of product release testing (8, 9, 13) . Reflecting progressive implementation of potency testing, in early clinical development, results may be presented "for information only" without a specification. Various 
Potency assay strategy for CTPs
To facilitate biologic characterization of the product, it is first necessary to develop a theory for the MOA and to outline how and why the product should work. As indicated in Figure 1 and The (hypothesized) mode of action is the foundation for potency development
In the early stages of product development, there are likely to be several theoretical MOA, and the MOA is likely to be multifactorial for most CTPs. These theories all should be considered when embarking on biologic characterization, and quantitative methods should be explored to measure them. Certain assays would be unsuitable for defining specifications because biologic assays are often complex in themselves, and read-outs require days or weeks. However, assays that correlate with the intended clinical effect or at least measure a characteristic for Table III . Pathway to developing a potency strategy for cell therapy products.
Preclinical research and development 1. Understand the biologic basis of the disease indication your CTP aims to treat 2. Define the realm of relevant biologic functions that your CTP possesses (literature searches, screening experiments) 3. Develop a hypothesis-driven, scientific rationale for the manner in which your CTP will correct or modify the pathology in the indication of choice 4. Create a matrix of assays that quantitatively measure the relevant biologic functions that align with the scientific rationale for treatment of the disease by your CTP Product development and clinical assessment 5. Use the matrix of assays throughout product development to monitor if and how the biologic functions vary depending on a. The manufacturing process (e.g., culture vessels, cell propagation length, cell densities at seed and harvest, media composition) b. Donor-to-donor or batch-to-batch variability 6. Where feasible and appropriately powered, attempt to correlate clinical outcome with one or more assays for biologic functions. If there is a clear correlation, it will be straightforward to select the final "potency assay" for pivotal studies and beyond. This is a low-probability scenario. A direct correlation between measured function (potency) and clinical outcome is in reality rarely observed in early-or mid-stage development, and it is currently not a requirement 7. Set specifications based on all relevant manufacturing and clinical data a. During early-stage clinical testing wide specifications can be used in light of the uncertainties associated with the (lack of) robustness and relevance of any one assay b. Specifications can be tightened after more process knowledge is acquired throughout clinical testing with respect to donor-to-donor or batch-to-batch variability which there is clear evidence that it is part of the MOA are valid starting points. Successful biologic characterization not only would guide the identification of appropriate potency assays but also would provide an arsenal of methods that can be employed in comparability studies (discussed later) to support future process changes during development and post-marketing. To ensure that the relevant needs continue to be addressed, it would be necessary to evaluate the employed methods continually against new data relating to the MOA and adapt as necessary. It might even become prudent to change the potency assay at a later stage if clear evidence suggests the original theory was flawed or if substantially better analytic methods become available. In certain cases (e.g., when the MOA is hard to define), discovery-driven methods such as microarray, proteomics or other types of analysis may be able to identify potential potency biomarkers. However, in most cases, the best starting point is the definition of one or more theoretical MOA.
Developing a strategy
The process of potency assay development for CTP should start with a "potency strategy," based on a scientific rationale and basic research and taking into account regulatory principles. This strategy, summarized in Table III , is typically built in stages from preclinical research and development to clinical testing. For instance, if the product is thought to elicit a particular response in the recipient (e.g., inhibit an inflammatory response), one or more tests should be developed that specifically measure that response. If the cells might suppress an inflammatory response that might be mediated through antiinflammatory cytokines, cell-cell contact or both, investigation into the exact mechanism may identify a potential potency assay. When part of the MOA is known, biologic characterization should focus on that, with the intention to develop a potency assay associated with that characteristic. When the MOA is not yet understood, a matrix of more general measures of biologic activity likely needs to be employed until the MOA is sufficiently understood. Regardless of the initial situation, potency determination needs to be constantly reviewed and refined in the light of new data throughout development. Putative measures of potency should be identified during pre-clinical evaluations when efficacy studies are being evaluated in animal models. Typically, a general understanding of MOA is elucidated during this phase of development when data are emerging to suggest that the cell product can elicit a curative effect in an animal. Identifying potential measures of potency early in clinical development should evolve from pre-clinical studies (14) . For production of material for early clinical trials, potential assays should ideally be tracked with a targeted acceptance range. However, as indicated previously, in cases where it is not yet possible to define a preliminary specification, it may be justified to collect data for information only. For later phase (pivotal) clinical trials in which efficacy is being evaluated, it is important to demonstrate manufacturing consistency, which can be ensured only through validated assays with defined acceptance limits. Without this assurance in place, doubt would remain as to whether all trial subjects were exposed to the product with a consistent potency that is stable over the shelf life, leading to difficulties in assessing the overall risk versus benefit.
Practical considerations

Potency-worth the investment?
First, the objective is to manufacture a consistent product that elicits a consistent clinical response. Without product consistency, there is little chance of observing consistent clinical effects or successfully demonstrating efficacy. As discussed, showing consistency of physicochemical characteristics is important but should be secondary to consistency of biologic function.
After meaningful measures of biologic function have been established, process development can focus on maximizing the desired biologic characteristics of the product and minimizing the undesired effects, allowing processes that result in a higher potency per unit of content (e.g., number of cells) to be identified. Additionally, because the relationship between cell number and potency is often obscure or unknown, potency measures may allow the relationship between cellular content and potency to be more clearly understood and the dose (typically defined in units of potency for biologic products) to be more clearly defined such that the minimum effective dose can be established. Identifying the minimum effective dose of the product makes commercial sense because the cost per dose is related to the number of cells required. This approach is also aligned with current agency expectations (11, 15) . In conclusion, the characterization required to explore the relevant biologic functions has greater utility than just the identification of potency assays in that it provides the basis for development and evolution of the product that enables commercial exploitation of the CTP.
Comparability-addressing inevitable change
The second, and perhaps equally important, role of biologic characterization is to provide relevant tools that allow comparability to be established following process changes, which inevitably occur during both development and post-market authorization. Whenever changes are made to the manufacturing process, potency determination forms an integral part of the confirmation that the relevant biologic characteristics are retained. This confirmation needs to be supported by additional biologic assays (in vitro and where necessary in vivo). This support is particularly important where constraints of time and material (e.g., for autologous products or other products with a short shelf life) limit the tools available for potency determination to "simple" or surrogate physicochemical parameters. Even in the absence of these kinds of constraints, potency evaluations are needed to address potentially routine changes, such as suppliers or sources of critical raw materials, without necessitating clinical validation before they can be implemented. Temporary cessation of supply, while data are collected and regulatory approval is sought, could seriously damage the commercial reputation of the developer and result in significant commercial losses.
During development, significant changes may become clinically qualified by the next clinical study phase. However, following market authorization, implementing process changes with an insufficient characterization tool set would necessitate confirmatory non-clinical or clinical data (or both), adding significant cost and time to any process changes or site moves. In contrast to small molecules and some other biologics, conventional pharmacokinetics and pharmacodynamics cannot be measured, and so in the absence of a suitable biomarker, clinical qualification may require a lengthy clinical follow-up, depending on the indication and nature of the product.
Potency is central to confirming product stability
Although viability may appear to be the obvious characteristic indicating stability, viable cells may lose biologic function during storage. Whether loss of biologic activity precedes cell death by minutes, hours or days cannot be known unless a reliable measure of biologic function is included in stability studies. Even in cases where other characteristics may be more sensitive stability indicators, it is still relevant to include potency in all stability programs because ultimately no product should be released that does not have the stated potency for the full duration of the shelf life; this is also a fundamental regulatory principle (13) . Until a potency assay is defined and qualified, product shelf life cannot be confirmed, and there is a risk that a product used during development might not be potent for the whole assumed shelf life or may be more sensitive to storage conditions than other parameters suggest.
The stability of a CTP is usually a key driver when considering product formulation (e.g., fresh versus frozen). This is a key decision that needs to be addressed early in development because it has a significant impact on the approach to commercialization. If viability is used early on to determine that the product has a sufficient shelf life to be commercially viable, it might be disastrous to find later that the shelf life is significantly shorter because potency is lost over time in viable cells. Such a revelation might postpone the development program months or years (if trials need repeating) while the product is re-formulated and work is undertaken to demonstrate the altered product is comparable.
Reference materials-confirming relative potency
The need for reference materials is a fundamental concept in the quality control of all medicinal products, yet this poses significant and specific challenges for CTPs. The normal approach is to allocate a representative batch of product, use this as the master reference material (RM) and qualify working RM that can be used for batch release, comparability and other needs. In situations where no international reference standard exists (as with CTPs), RM is usually used to assign relative potency to the potency assay, ensuring the measurement of potency is normalized over many batches. Likewise, RM can be important for other specifications and comparability studies.
With CTPs, preparing RM can bring significant challenges because manufacture of large quantities of product may be impossible even if multiple batches are combined. However, any measurement of potency is seriously compromised if no RM is available to confirm performance of the assay and to allow relative potency to a known batch to be confirmed. In the absence of the ability to prepare a product RM, other approaches to develop suitable RM need to be considered; this is a very relevant consideration but goes beyond the immediate scope of this review.
The difficulties of developing RM should not be dismissed lightly; potency assays are often complex with wide variations, and there is a risk of assay drift and, perhaps more importantly, process drift. Trending alone is unlikely to be successful because many analytic methods for CTPs have broad ranges meaning it could be months or years before even significant trends can be identified, if at all. Considering that CTP manufacturing processes often involve multiple manual steps and that bioassays can also be sensitive to operator technique, it is essential to control these potential sources of variability. If a batch of product fails release testing, without RM it may be difficult to identify whether the root cause of the problem is within the process or the assay.
No potency assay is complete until suitable RM has been developed to ensure the results from batch to batch can be reliably compared. RM is central to confirming product consistency in general and is vital to confirm the consistency of potency determination.
Considerations for the assay itself
It is important to calculate an overall cost impact for a particular assay or matrix of assays to release a batch of product with a final metric of "cost per product unit." The cost per product unit is affected most dramatically by batch size and how many units are required for testing to release the batch for use. Choosing the number of product units to be tested is not trivial, and many factors are likely to contribute to the decision. Testing most often is performed on the final product after packaging. In some instances, in-process testing may also be required before fill or finish. Release testing of a product is meant to ensure that the batch as a whole meets specifications as well to confirm that the first and last product units manufactured are of equivalent quality.
These calculations should not deter developers from employing a matrix of potency testing during development because, as discussed at length throughout this review, identifying assays that define potency may be difficult. By using a matrix of assays, the assays that provide the most useful measure of potency can be selected and, where necessary, developed further into a potency test appropriate for commercial needs and satisfactory to regulators. The data collected from the matrix of assays employed over development provide a basis as well as historic data for comparability. The value of these data can be hard to judge in the short-term, but if not collected at the time, the data are lost forever.
Another important commercial consideration for potency assays are the reagents used. Some materials used in analytic methods, especially for potency assessment, may be as critical to product quality as the raw materials used in the manufacture process. Consequently, their supply continuity and quality should be ensured in the same way. Key reagents such as indicator cell lines and monoclonal antibodies can be hard to replace and perhaps impossible without RM.
Reported potency assays in the field and case studies
The previous sections focused on practical and developmental issues concerning potency assays, their development and use. This section illustrates the realities, pitfalls and solutions for the various obstacles in this iterative process through five real-life case studies. These examples span various classes of cell products, including autologous, allogeneic, adherent and non-adherent products from different tissue sources, and highlight a diversity of assays and surrogates that were identified to support potency evaluation for each individual CTP.
Various CTP potency assays have been reported in the literature and public meetings, and some examples from the field are summarized in Table IV . Five case studies are described; detailed descriptions, illustrated with relevant data sets, are presented as Supplemental material to this review, available online.
Case study 1
Case study 1 concerns development of a potency assay for ChondroCelect (Tigenix, Leuven, Belgium), a commercial CTP for autologous chondrocyte implantation in cartilage repair. This autologous chondrocyte product is indicated for the treatment of cartilage defects. In vivo cartilage formation was correlated with marker gene expression and in vivo chondrogenesis, supporting the validation of a potency assay based on specific molecular marker expression in a quantitative reverse transcriptase polymerase chain reaction-based assay.
Case study 2
Case study 2 concerns development of a potency assay for Xcellerated T Cells (Xcyte Therapies, Seattle, WA, USA), an autologous activated T cell therapy product for treating chronic lymphocytic leukemia (CLL). The proposed MOA for Xcellerated T Cells on leukemic B cells in CLL was that T cell defects were corrected via stimulation using magnetic beads coated with anti-CD3 and anti-CD28 antibody, leading to restored T cell functionality and subsequent TNF receptor superfamily, member 6 (FAS)-mediated killing of leukemic B cells after contact with infused CD154-expressing T cells. Response of Xcellerated T Cells to re-stimulation in vitro with plate-bound anti-CD3 and anti-CD28 monoclonal antibodies (mimicking in vivo reactivation) was shown to be tightly correlated to restored functionality. A cell-based potency assay was developed using flow cytometry for CD154 expression. This plate-bound re-stimulation assay was validated and implemented for quality control batch release potency testing of Xcellerated T Cells.
Case study 3
Case study 3 concerns development of a potency assay for a regulatory T cell (Treg) product Athelos (NeoStem, New York, NY, USA) for the treatment of graft-versus-host disease (GVHD) and other immune-based diseases. Athelos is in the pre-clinical stage for development of a Treg product for the treatment of GVHD, autoimmune diseases and solid organ transplant tolerance. The development of a Treg potency assay for final product characterization and release will be based on a mechanism involving cell-cell contact to use the ability of Tregs to inhibit anti-CD3/anti-CD8 activated conventional T cell (Tcon) proliferation in vitro. Suppression of T cell activation markers CD69 and CD154 will be determined by flow cytometry as a measure for Treg potency.
Case study 4
Case study 4 concerns development of a potency assay for Amorcyte, AMR-001 (NeoStem), an autologous adult bone marrow-derived CTP for cardiac repair after myocardial infarction. AMR-001 is being evaluated for the treatment of damaged heart muscle after acute myocardial infarction (AMI). The potency assay for AMR-001 was developed based on the putative MOA of infused CD34 þ
CXCR4
þ cells that home to damaged tissue via a gradient of stromal-derived factor 1 (SDF-1) to facilitate tissue repair and vascular regeneration. During phase I studies, several cell characteristics of AMR-01 were evaluated to correlate cell product release criteria to clinical activity. The relative mobility in an SDF-1 gradient of CD34 þ cells in the AMR-001 product was the only parameter that correlated to clinical benefit, and an in vitro migration assay of CD34 þ CXCR4 þ cells in an SDF-1 gradient was developed as the potency assay for AMR-001.
Case study 5
Case study 5 concerns development of a potency assay for MultiStem (Athersys, Cleveland, OH, USA), an adult allogeneic bone marrow-derived stromal CTP, in treatment of myocardial infarction. MultiStem is an adult adherent stem cell product. Pre-clinical models of ischemia demonstrated that MultiStem induces angiogenesis in vivo and that increased vessel formation correlates with efficacy and treatment. An in vitro angiogenesis assay established vascular endothelial growth factor (VEGF), chemokine ligand 5 (CXCL5) and interleukin (IL)-8 secreted by MultiStem product to be required for the induction of angiogenesis. A necessary threshold of angiogenic factor expression was established using the in vitro angiogenesis assay, and detection of these factors by enzyme-linked 
ELISA, enzyme-linked immunosorbent assay; HES, human embryonic stem cell; PCR, polymerase chain reaction; SDF-1, stromal cell-derived factor 1; TNFR1, tumor necrosis factor type 1 receptor; VEGF, vascular endothelial growth factor. immunosorbent assay (ELISA) was defined as the surrogate potency assay (19) .
Conclusions
The first hurdle in potency determination is to understand the MOA of the CTP, and because this requires biologic characterization, such studies should by their nature identify putative assays. Biologic characterization encompasses not only in vitro assays developed as part of manufacturing quality but also non-clinical and clinical data because the purpose of these assays is to understand the relevant (and undesired) biologic effects of the product. In a well-conceived development program, potential potency assays should be a natural by-product, albeit requiring some adaptation into test methods suitable for product release. Although the preferred potency assay for product release would provide a quantitative biologic measure of relevant function, such assays are not always suitable for release purposes because of product-specific issues such as batch size and time limitations, a point that is acknowledged by regulators. It is reasonable where such arguments are justified to use simpler physicochemical methods as surrogates for potency but only where they can be correlated to a true measure of relevant biologic function. More broadly, this review puts the measurement of relevant biologic function and potency into context within the broader topic of product development. The primary purpose of potency determination is to confirm that the relevant biologic activity of the product is present to the expected level at release. Likewise, it is essential to confirm that the relevant biologic activity is retained throughout the claimed shelf life because viability alone does not achieve this. The second and perhaps equally important role for potency determination is to provide the tools for comparability assessment after process changes (e.g., process improvements, new sites, changes of scale). Although potency alone is unlikely to be sufficient in many cases, the additional biologic assays explored during characterization provide an arsenal of methods to confirm that the essential characteristics of the product have been retained. Finally, potency assays are critical to confirming other aspects of stability (e.g., in-use stability) and compatibility of the product with devices (where applicable). The return on early, systematic and prolonged investment in a bona-fide potency program for CTPs would mitigate the risk of costly product failure in late-stage development and enhance the likelihood of commercial success.
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Case studies for potency assay development for cellular therapy products
In this supplemental section, we present the five case studies with more detail, including certain relevant data sets. They highlight different hypotheses and approaches used for the development of potency assays for different classes of CTPs at different stages of product development. Products include autologous chondrocytes for cartilage repair, T cell products for treatment of leukemia or immune disorders, and stromal or non-adherent bone marrow-derived cell products for treatment of AMI. Each case study describes a different path from MOA hypothesis toward the identification of potency markers that enable simple and accurate quantitation in vitro. The resulting potency assays include quantitative polymerase chain reaction, fluorescent activated cell sorter (FACS), ELISA and cell migration assays. These case studies directly underscore the concept that potency evaluation should be based on the specific characteristics of each individual CTP and that the assay adequacy needs to be developed and evaluated on a case-by-case basis. The five specific case examples are as follows:
Case study 1: development of a potency assay for ChondroCelect (Tigenix, Leuven, Belgium), a commercial CTP for autologous chondrocyte implantation in cartilage repair Case study 2: development of a potency assay for Xcellerated T Cells (Xcyte Therapies, Seattle, WA, USA), an autologous activated T-cell therapy product for treating CLL Case study 3: development of a potency assay for a Treg cell product for the treatment of GVHD and other immune-based diseases (Athelos, a NeoStem Company, New York, NY, USA) Case study 4: development of a potency assay for AMR-001 (Amorcyte, a NeoStem Company, New York, NY, USA), an autologous adult bone marrow-derived CTP for cardiac repair after myocardial infarction Case study 5: development of a potency assay for MultiStem (Athersys, Cleveland, OH, USA), an adult allogeneic bone marrow-derived stromal CTP, in treatment of myocardial infarction Case study 1: development of a potency assay for ChondroCelect, a commercial CTP for autologous chondrocyte implantation in cartilage repair
Product specifics
ChondroCelect received final marketing authorization as an Advanced Therapy Medicinal Product by the EMA in October 2009. It is indicated for the treatment of symptomatic, isolated, full-thickness cartilage defects of the femoral condyle and delivered as a sterile suspension of ex vivo expanded, autologous chondrocytes in excipient medium. ChondroCelect is surgically applied in a two-step procedure known as autologous chondrocyte implantation. In the first step, a cartilage biopsy sample is obtained arthroscopically from a minor weight-bearing region of the joint to provide the starting material for the cell expansion process. In the second step, the isolated and expanded chondrocytes are implanted in the defective cartilage in a mini-arthrotomy.
Strategy
The use of isolated and expanded chondrocytes in autologous chondrocyte implantation has been documented for many years, with original clinical investigations performed by Brittberg et al. (1) . A major challenge in the field is obtaining a sufficient number of high-quality cells at the end of the ex vivo culture process that retain the capacity to form stable, structured cartilage in vivo. It has been widely reported that culture of isolated chondrocytes results in progressive loss of the chondrogenic phenotype and consequently loss of good cartilage repair abilities (2,3). It was known at the outset of development that limiting cell expansion and assessing the potency of the final, expanded cellular product would be crucial. In developing a potency test for ChondroCelect, a series of biologic tests relevant for assessing cartilage quality were investigated. Subsequently, the correlations between in vivo cartilageforming capacity and surrogate in vitro and molecular assays were determined, where the latter could serve as the routine potency measure.
Potency assay for ChondroCelect
The first step in developing a potency test for ChondroCelect was to establish an assay to measure cartilage-forming capacity in an in vivo environment but using a simpler model than surgical orthotopic autologous chondrocyte implantation in a large animal (Supplementary Figure 1) . To this end, the ectopic cartilage formation assay (ECFA) was developed. In this model, cells are injected intramuscularly, and cartilage formation is evaluated based on a histologic score. Using the ECFA, different populations of cultured chondrocytes could be functionally distinguished, ranging from chondrocytes that have retained the ability to form stable, hyaline-like cartilage tissue to chondrocytes that have lost all cartilage-forming capacity through de-differentiation during culture. These populations were screened for molecular marker expression using a micro-array approach to identify genes that correlated positively or negatively with cells able to produce stable hyaline cartilage in the ECFA model. Using this approach, a ChondroCelect potency assay was established based on molecular marker expression. The relevance of this surrogate assay was confirmed through correlations with the ECFA, which was correlated with the large animal efficacy model. Additional work showed that the surrogate molecular assay also correlated well with other relevant in vitro models of chondrocyte functionality, such as the well-described three-dimensional chondrogenic pellet assay (4). The surrogate potency assay was developed and validated for use in routine production, whereas the additional in vivo and in vitro assays validated during development provide a more complete picture of product biologic activity and can be used as important tools to support process and assay changes.
In conclusion, based on the combination of the aforementioned studies, an overall picture of cellular potency could be constructed, where in vivo cartilage formation was correlated with marker gene expression and in vitro chondrogenesis. Taken together, these studies supported the validation of a potency assay based on specific molecular marker expression. This quantitative reverse transcriptase polymerase chain reaction-based assay is both practically feasible in a routine manufacturing setting and relevant because it correlates with an extended set of assays demonstrating chondrogenic functionality.
Note: ChondroCelect is a commercial medicinal product; some aspects of the potency assay are proprietary and not disclosed.
Case study 2: development of a potency assay for Xcellerated T Cells, an autologous activated T cell therapy product for treating CLL
Product specifics
Xcellerated T Cells were developed by Xcyte Therapies (now defunct) for the treatment of multiple indications, including CLL. A hallmark of CLL is Supplementary Figure 1 . Multi-assay analysis of ChondroCelect. Multiple cell populations, ranging from phenotypically stable chondrocytes to increasingly de-differentiated cells with reduced cartilage-forming capacity were evaluated in vivo, in vitro and at a molecular level. (A) In a goat model of autologous chondrocyte implantation, stable cartilage formation was observed using phenotypically stable chondrocytes, whereas the quality of the repair tissue was reduced using de-differentiated chondrocytes. No significant repair could be observed in the negative control dermal fibroblast group. (B) The same cell populations were evaluated in an ECFA in the nude mouse. In this model, phenotypically stable chondrocytes formed tissue displaying all the hallmarks of hyaline cartilage, whereas de-differentiated chondrocytes formed a less mature and more fibrous tissue. Only fibrous tissue was evident in the negative control of dermal fibroblasts. (C) De-differentiation status was shown to correlate with gene expression profile based on specific molecular markers. Based on correlations with the in vivo models, this assay was validated as a surrogate potency assay for routine product testing. PCR, polymerase chain reaction. the accumulation of leukemic B cells concomitant with immunologic abnormalities in the T-cell compartment (5,6). The Xcellerate treatment hypothesis was that potent activation of T cells in the patient would reverse T-cell functional defects, allowing normal T-cell orchestration of the immune response, which would reverse abnormal accumulation of leukemic B cells through restoration of normal homeostatic mechanisms. T cells from the patients were activated using Dynabeads CD3/CD28 CTS immunomagnetic beads (Life Technologies, Grand Island, NY, USA) bearing covalently attached antibodies against the T-cell surface receptors CD3 and CD28. Activated cells were expanded in culture and showed restored expression of key markers and cytokines along with restoration of response to allogeneic stimulation (mixed lymphocyte reaction response). 
Strategy
The proposed MOA for Xcellerated T Cells on leukemic B cells in the setting of CLL was that T-cell defects were corrected via stimulation using Dynabeads CD3/CD28 CTS, leading to restored T-cell functionality and subsequent FAS-mediated killing of leukemic B cells after contact with infused CD154-expressing T cells. Response of Xcellerated T Cells to re-stimulation in vitro with plate-bound anti-CD3 and anti-CD28 monoclonal antibodies (mimicking in vivo reactivation) was shown to be tightly correlated with restored functionality. A cellbased potency assay was developed using this approach. Both flow cytometry-based and ELISAbased assays were used to assess a panel of markers associated with normal functionality, including rapid up-regulation of surface markers (CD25, CD54, CD137, CD154), rapid secretion of cytokines (granulocyte-macrophage colony-stimulating factor, interferon-a, tumor necrosis factor-a) and rapid down-modulation of CD62L. The assay was set up to compare the response of Xcellerated T Cells from patients with CLL with their non-manipulated T-cell counterparts, with the end goal of creating a simple, reproducible, low-variance assay that would measure a single marker as the correlate for restored T-cell functionality.
Potency assay for Xcellerated T Cells
To enable routine use of the potency assay in quality control lot release and stability testing, development focused on establishment of a standardized method with a robust, consistent read-out. Assay parameters that were investigated and optimized included the concentration of the plate-bound anti-CD3 and anti-CD28 antibodies for re-stimulation, the time of exposure to re-stimulation and the incorporation of positive and negative controls to assess system suitability. The induction of cytokine secretion and expression of various key surface markers all correlated well with normalization of T-cell function (Supplementary Table I ). CD154 expression was selected as the ultimate potency assay marker because CD154 expression was believed to be directly correlated with the proposed therapeutic MOA. The assay was validated for analysis of CD154 (CD40L) induction because the sensitivity, rapidity, reproducibility and low variance were optimal for CD154.
In conclusion, when analyzed in the potency assay, final product Xcellerated T Cells exhibit faster kinetics and greater levels of up-regulation of CD154 than the autologous peripheral blood T cells used as the starting cells for the Xcellerate Process (Supplementary Figure 2 ). Xcellerated T Cells produced from patients with B-cell CLL demonstrate a robust and reliable response in the potency assay, with a mean fold increase in expression of CD154 of 21.0 AE 4.3 for CD4 þ T cells and 11.9 AE 3.7 for CD8 þ T cells (n ¼ 26). The plate-bound re-stimulation assay was validated and implemented for quality control lot release potency testing of Xcellerated T Cells.
Case study 3: development of a potency assay for a regulatory T cell product for the treatment of GVHD and other immune-based diseases
Product specifics
Athelos, which is 80% owned by NeoStem, is developing a Treg product for the treatment of GVHD, autoimmune diseases, and solid organ transplant tolerance (9e11). The Athelos Treg program is in the pre-clinical and phase I development stages. Natural Tregs (nTregs) are thymus-derived T cells (15, 16) . One of the Athelos Treg cell therapies will use an in vitro expanded nTreg product. nTregs have been shown to suppress activated CD4 þ and CD8 þ effector cells and prevent or treat GVHD or autoimmune disease in several animal models (9) . Several phase I trials are underway at the present time or have been completed at academic institutions where the safety of Tregs has been shown, and efficacy in preventing GVHD has been suggested (17) .
Strategy
Studies suggest that nTreg suppression of Tcons may be mediated through several different MOA, but cell-cell contact appears to be an important mechanism (18) . In vitro, this activity can be demonstrated by the inhibition of in vitro polyclonally activated Tcons when co-cultured with Tregs. The development of a Treg potency assay for final product characterization and release was based on this Supplementary 
Comparing normalized fold increase or decrease in marker expression between Xcellerated T Cells and non-Xcellerated T Cells using an anti-CD3/anti-CD28 coated plate re-stimulation format or allo-response (mixed lymphocyte reaction) assay. Rapid assay kinetics, maximum fold change in marker expression and low variance were considered desirable read-out attributes (reflected by bold in table) . GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; TNF, tumor necrosis factor.
Supplementary Figure 2 . CD154 expression on CD4 þ cells before and after expansion and re-stimulation. Various antibody coating concentrations were evaluated for optimized marker induction, as were kinetics of induction to design final re-stimulation assay format. In this example, induction of CD154 (CD40L) on CD4 þ T cells was measured by FACS.
mechanism to use the ability of Tregs to inhibit anti-CD3/anti-CD8 activated Tcon proliferation in vitro. Earlier versions of the in vitro assay to determine Treg suppression of Tcon proliferation used either 3 H-thymidine or carboxy-2 0 ,7 0 -dichlorofluorescein diacetate, succinimidyl ester (CSFE) intracellular dye to monitor cell expansion. Employing the recently developed commercial FACSbased assay kit developed by Becton Dickinson Biosciences (Franklin Lakes, NJ, USA), suppression of T cell activation markers CD69 and CD154 will be used to assess Treg potency (19) . The FACS kit has been performed in parallel with assays using CSFE and has shown consistent comparability in determining Treg activity (20) . The advantages of using this kit are same-day or next-day results (vs. up to 5 days using 3 H-thymidine or CSFE) and reduced technical hurdles in preparing and performing the assay. Both of these enhancements result in an overall reduction in assay variability.
Potency assay
Several components of the FACS-based system are critical to the reproducibility and robustness of this assay. Two particularly important factors are the source and quality of the Tcons and the type of stimulation used to activate them. For the treatment of GVHD or solid organ transplant tolerance in which the nTreg product is donor-specific and patient-specific, freshly isolated Tcons may be used to determine potency of the final product. However, in the scenario of developing an allogeneic "off-theshelf" product, the donor-to-donor variability of using fresh Tcons may make lot-to-lot comparisons difficult. Tregs can suppress third-party Tcons, and the generation of a bank of frozen peripheral blood mononuclear cells from a single or defined number of donors is an approach that would reduce interassay variability for both patient-specific and "offthe-shelf" products. For the Athelos potency assay, the strategy is to create a qualified bank of the peripheral blood mononuclear cells with the best signal-to-noise ratio for use in subsequent potency assays. Assay development during the pre-clinical research phase evaluated several methods to activate Tcons, including soluble anti-CD3 antibody, plate or bead bound anti-CD3 with soluble anti-CD28 and beads bound with both antibodies. Titration studies evaluating several bead-to-Tcon ratios demonstrated that commercial anti-CD3/anti-CD28 beads (Dynabeads CD3/CD28 CTS; Life Technologies) gave the most consistent activation of Tcons. Development of the Athelos assay will seek the optimal level of Tcon activation that is still suppressible by Tregs.
In conclusion, an nTreg in vitro potency assay based on the cell contact-dependent mechanism of suppression of Tcon activation and proliferation has been developed. For both patient-specific and allogeneic "off-the-shelf" Treg products, an nTreg potency assay using a commercial flow cytometry assay will be used. Third-party peripheral blood mononuclear cells will be screened and banked as a source of Tcon responders to reduce inter-assay variability. The assay described here is currently in development and is being implemented for research use only.
Case study 4: development of a potency assay for AMR-001, an autologous adult bone marrow-derived CTP for cardiac repair after myocardial infarction
Product specifics
AMR-001 is an adult bone marrow-derived cell product manufactured by PCT (Allendale, NJ, USA) for Amorcyte, a NeoStem Company. AMR-001 is being evaluated for the treatment of damaged heart muscle after AMI. Over the last few years, several clinical trials evaluated the infusion of stem cells for AMI and showed promising results (21, 22) . AMR-001 has completed a phase I clinical trial that showed a dose-related significant improvement in perfusion (23) . Patients received doses of 5, 10 or 15 million CD34 þ cells. Patients receiving !10 million cells (n ¼ 9) showed significant improvement in resting perfusion rates at 6 months compared with patients receiving 5 million cells (n ¼ 6) and control (n ¼ 15), as measured by the single photon emission computed tomography (SPECT) total severity score (À256 vs. þ13; P ¼ 0.01). The data also showed that patients receiving !10 million cells experienced a trend toward improvement in ejection fraction (þ4.5% vs. þ0.69%), end-systolic volume (À5.7 mL vs. þ3.5 mL) and infarct size and tissue death secondary to loss of adequate blood supply (À7.4% vs. À5.3%) at 6-month follow-up. No study-related significant adverse events were reported.
Strategy
The potency assay for AMR-001 was developed based on the putative MOA of AMR-001 that the infused CD34 
CXCR4
þ cells home to damaged tissue via a gradient of stromal cell-derived factor-1 (SDF-1) where they facilitate tissue repair and vascular regeneration (24e29). After AMI, damaged and dying myocardiocytes under ischemic stress and hypoxia in the peri-infarct zone produce hypoxia-inducible factor 1 (HIF-1) and vascular endothelial growth factor (VEGF), two pro-angiogenic factors. HIF-1 also induces the production and release of SDF-1, a ligand for CXCR4. SDF-1 produced in the damaged region attracts mobilized CD34 þ CXCR4 þ stem cells to the infarct site to initiate repair of damaged tissue. AMR-001 is infused via the infarctrelated artery 5e11 days after ST segment elevation myocardial infarction-the optimal time frame for cellular intervention, after the pro-inflammatory "hot phase" and before permanent scar formation. The infused CD34 þ CXCR4 þ cells home to the at-risk tissue via the SDF-1 gradient, inducing neoangiogenesis and resulting in functional benefit to the patient.
Development of the potency assay is based on the putative MOA of AMR-001, in which greater cardiac repair is correlated with the ability of stem cells to migrate to the peri-infarct zone. During phase I studies, several cell characteristics of AMR-01 were evaluated to correlate criteria for cell product release to clinical activity. Parameters evaluated included number of CD34
þ cells, colony-forming unit-granulocyte macrophage forming ability in vitro and relative activity in an SDF-1 migration assay. As shown in Supplementary  Figure 3 , the relative mobility in an SDF-1 gradient of CD34 þ cells in the AMR-001 product was the only parameter that correlated to clinical benefit as measured by the resting hypoperfusion score (Resting Total Severity Score) and reduction in the infarct size as a percentage of the left ventricular area.
Potency assay
The in vitro migration assay of CD34 þ CXCR4 þ cells in an SDF-1 gradient was developed based on the assay as originally described by Jo et al. (30) . Conversion of the research assay into an assay suitable for product release and quality assurance required the evaluation and standardization of reagents including qualification of the culture media and recombinant SDF-1. Additional factors examined included optimization of the kinetics and time needed for sufficient CD34 þ cell migration and standardization of enumerating migrating cells. To reduce variability in enumerating migrating cells in the assay by microscopic visualization and colony counting, the AMR-001 assay incorporates flow cytometry analysis of viable CD34 þ cells to determine the number of migrating cells.
In conclusion, development of the potency assay for AMR-001, a bone marrow-derived CD34 þ CXCR4 þ cell product for the treatment of AMI, is described. The use of the SDF-1 migration assay is based on pre-clinical data supporting the hypothesis that repair of ischemic myocardium requires migration of infused stem cells to the site of injury. The ability of the cell product to migrate in the SDF-1 mobility assay was correlated to clinical benefit. Although migratory ability of the stem cells may not be directly involved with the actual mechanism of repair of cardiac tissue, the data suggest that the number of stem cells homing to the site of injury is an important factor in the overall efficacy of the therapy. During a phase I study, cell products were assessed for numerous characteristics, including phenotype (CD34 þ and CXCR4 þ or VEGFR2 þ ), granulocyte macrophage colony formation and SDF-1 mobility. Potency of the AMR-001 product correlated to the quality of the cell product based on the mobility assay. Case study 5: development of a potency assay for MultiStem, an adult allogeneic bone marrow-derived stromal CTP, in treatment of myocardial infarction
Product specifics
MultiStem is an adult adherent stem cell product manufactured by Athersys. MultiStem is currently under clinical evaluation in phase I and II studies as adjunct therapy for treatment of ischemic and inflammatory processes that occur after AMI, hematopoietic stem cell transplantation and stroke and during ulcerative colitis. MultiStem has shown beneficial effects in a broad array of pre-clinical disease models, which lends support to a model of multimodal therapeutic activity of the cell product that, depending on the disease pathology, may consist of modulation of inflammation and cellular immune activity, cytoprotection and support of angiogenesis (31e34). Clinical results in patients with AMI receiving MultiStem demonstrate a strong safety and benefit profile (35) . The development of a potency assay is presented in which production of a panel of cytokines required for the specific angiogenec potential of MultiStem is measured. This information is presented to highlight the rationale and potential strategy for stromal cell therapy potency assessment. This assay is not as yet a regulatory approved procedure.
Strategy
Preclinical models of ischemia demonstrated that MultiStem induces angiogenesis in vivo, and the increase in vessel formation induced by MultiStem treatment correlates with efficacy and treatment benefit (31, 33, 36) . A well-established angiogenesis assay, human umbilical vein endothelial cell tube formation assay (37) , was used to demonstrate that MultiStem can induce angiogenesis in vitro and in vivo. Multiple pro-angiogenic factors were shown to be secreted by MultiStem, including VEGF, CXCL5 and IL-8. Using the human umbilical vein endothelial cell tube formation assay, immunodepletion studies demonstrated that these three angiogenic factors, VEGF, CXCL5 and IL-8, are necessary for MultiStem-induced angiogenesis, with significant reduction in tube formation in the absence of any of these factors. Adding back increasing amounts of these cytokines into depleted conditioned media established the lower limits of each of these cytokines required to induce angiogenesis (Supplementary Figure 4) . Mesenchymal stromal cells, produced according to classic culture procedures, lacked significant production of CXCL5 and IL-8, and conditioned media from mesenchymal stromal cell cultures did not provide stable tube formation activity in vitro. Detection of VEGF, CXCL5 and IL-8 by ELISA was deemed to provide an adequate set of surrogate potency markers with specificity for MultiStem activity in ischemic injury indications.
Potency assay
The lower limit of each of these factors required to induce angiogenesis was set as pass/fail criteria for the cells. ELISAs for VEGF, CXCL5 and IL-8 are commercially available and standardized for accuracy, precision and specificity by the manufacturer. To validate these assays further for potency testing and establish a positive reference for use in future lot testing, qualification of the assay using two operators and on two separate days was performed. These tests validated the assay as accurate and reproducible by correlating the amount of these factors in the conditioned media to levels secreted during clinical manufacturing runs. The levels of these factors detected across manufacturing runs are consistent and demonstrate that the cells produced significantly more of these factors than the minimum required to induce angiogenesis. Clinical manufacturing lots have shown consistent production of this cytokine
Supplementary Figure 4 . Mechanism of the angiogenic potential of MultiStem. VEGF, CXCL5 and IL-8 were individually immunedepleted from MultiStem conditioned media. These factors were subsequently added back in a dose-response curve to identify the minimum level needed to restore the angiogenic response. Endothelial growth factor medium (EGM) is a positive control, whereas endothelial basal medium alone (EBM) is a negative control.
panel at levels that range between 10-fold and 50-fold above required in vitro threshold levels.
In conclusion, an in vitro angiogenesis assay has been developed based on the level of cytokines, VEGF, CXCL5 and IL-8, secreted by MultiStem and demonstrated to be required for the induction of angiogenesis. A necessary threshold of angiogenic factor expression was established using the in vitro angiogenesis assay. By correlating the levels of these cytokines required to induce tube formation in vitro with levels of these factors found in the spent media from MultiStem manufacturing production runs, detection of these factors was defined as a surrogate potency assay with defined pass/fail criteria. Further assay development to qualify and validate this assay fully for regulatory approval is currently underway.
